Five AVTX executives sold shares on the same day. The stock had just surged 57% in a week. The lending market heard it too — availability has swung from near-zero to wide open.
On May 6, five senior Avalo Therapeutics insiders filed sales totalling over $2.3 million. The CFO, Chief Medical Officer, and Chief Legal Officer all sold. The CMO alone sold three separate tranches worth roughly $754,000. These were not small option exercises — the CFO sold across three transactions adding up to more than $695,000.
The 90-day net insider value across the stock is a net positive $5.5 million, suggesting prior accumulation. But the cluster of coordinated selling at the peak of a 57% weekly rally is the story here.
The insider selling sits in sharp contrast to a wave of bullish analyst revisions. Four firms raised price targets this week alone.
Piper Sandler lifted its target to $60 on May 11. Citizens went to $62. BTIG moved to $58 from $40. Wedbush raised to $40 from $29. All four maintained their existing buy-equivalent ratings. The consensus mean target is $47 — still more than double the current $21.57 close.
The bull case centers on AVTX-009, Avalo's IL-1β program targeting hidradenitis suppurativa. Bears point to stiff competition from established IL-17 inhibitors and a 35% estimated probability of approval.
Until this week, shares in AVTX were extremely difficult to borrow. Availability sat near zero from mid-April through May 5 — meaning virtually every share in the lending pool was already lent out. That is as tight as the borrow market gets.
Then the stock moved. Short interest dropped 12.3% in a week to 26.8% of free float. Cost to borrow fell to 1.20% from over 2.3% earlier in April. Availability has swung dramatically wider. Short sellers are covering, and the borrow squeeze that had persisted for weeks has unwound rapidly.
The ORTEX short score has dropped from 78.7 on May 4 to 69.5 as of May 7 — still elevated, but moving in one direction.
One group is not celebrating the rally. The put/call ratio hit 0.97 on May 8 — 2.3 standard deviations above its 20-day mean of 0.89. That is the highest options hedging demand in weeks. With insiders selling and short interest still above a quarter of the float, some options participants are buying protection against a reversal.
See the live data behind this article on ORTEX.
Open AVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
